INTRODUCTION {#s1}
============

Although ranking the fifth most common cancer, hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide \[[@R1]\]. There is a high incidence of HCC in China and other Asia-Pacific region \[[@R1]\]. Notably, China alone accounts for about 50% of all HCC cases in the world \[[@R1], [@R2]\]. There were several epidemiological features, such as marked variations between geographical regions, racial and ethnic groups, and sex. It has been revealed that men have a higher prevalence of HCC than women, i.e. the male:female ratio of HCC patients is \~2.65:1 in high-risk Chinese populations \[[@R2], [@R3]\]. Chronic infections with the hepatitis B or C viruses (HBV or HCV), exposure to dietary aflatoxin B as well as excessive alcohol drinking have been identified as major environmental risk factors of HCC \[[@R2], [@R3]\]. Since about 75% cases of HCC are associated with HBV infection in China \[[@R4]\], HBV infection is considered as one major risk factor for HCC. However, only 15% chronic HBV carriers suffer from HCC in their lifetime \[[@R2], [@R3]\], indicating that host genetic factors may also be involved in development of HBV-related HCC. This notion has been proved by several candidate gene and genome-wide association study (GWAS) on HBV-related HCC in eastern Asians \[[@R5]--[@R10]\].

To identify genetic factors associated with HCC, Clifford et al. conducted a comprehensive, genome-wide variation analysis (both genetic polymorphisms and copy number variations) in a population of unrelated Asian individuals \[[@R11]\]. After genotyping 386 Korean HCC cases and 587 Korean controls with the Affymetrix SNP6.0 assay, they found that the 3p21.33 *GLB1* rs4678680 G \> T polymorphism is most significantly associated with HCC risk (odds ratio \[OR\] = 2.27, 95% confidence intervals \[CI\] = 1.68--3.08, *P* = 6 × 10^−7^). *GLB1* encodes a member of the glycosyl hydrolase 35 family of proteins, which catalyzes the hydrolysis of a terminal betalinked galactose residue from ganglioside substrates and other glycoconjugates. Accumulated evidences demonstrated that GLB1 is involved in cell senescence \[[@R12], [@R13]\] and cancer development \[[@R13]--[@R16]\]. Senescence phenotype could be induced by increased SA-b-galactosidase staining and elevated *GLB1* mRNA expression, indicating the important role of GLB1 in cell senescence. During the long latency of tumor development, oncogene-induced senescence has emerged as a barrier to tumorigenesis including HCC. Chen et al. conducted a replication case-control study on the association of 1p36.22, 2q32.2--q32.3, 3p21.33, 8p12, 14q32.11 and 21q21.3 with HCC among 507 Chinese HCC patients and 3014 Chinese controls. However, they did not included *GLB1* rs4678680 G \> T single nucleotide polymorphism (SNP) in the study. As a result, it is still largely unclear if *GLB1* rs4678680 polymorphism plays a part in etiology of HCC in Chinese. Also, little or nothing has been known about functional significance of the *GLB1* rs4678680 SNP in HBV-related HCC. Therefore, we conducted two large independent case-control studies to investigate the association between the *GLB1* rs4678680 genetic polymorphism and risk for developing HBV-related HCC. To validate the biological function of the rs4678680 SNP *in vivo*, we examined the association between *GLB1* rs4678680 genotypes and its mRNA expression levels in normal liver tissues.

RESULTS {#s2}
=======

Allele frequencies and genotype distributions of *GLB1* rs4678680 SNP in cases and controls from the Shandong and Jiangsu sets are showed in Table [1](#T1){ref-type="table"}. The allele frequencies for rs4678680 G were 0.087 or 0.094 in cases and 0.059 or 0.058 in controls in Shandong or Jiangsu case-control set. All observed genotype frequencies in both cases and controls conform to Hardy-Weinberg equilibrium. Distributions of the rs4678680 genotypes were compared between HCC cases and controls. Frequencies of rs4678680 TT, TG and GG genotypes among HCC cases differed significantly from those among controls in either Shandong set (χ^2^ = 7.593, *P* = 0.022, *df* = 2) or Jiangsu set (χ^2^ = 16.14, *P* = 3.12 × 10^−4^, *df* = 2).

###### Genotype frequencies of the *GLB1* rs4678680 G \> T polymorphism among HCC cases and chronic HBV carriers and its association with HBV-related HCC risk

  Studies        Genotypes   HCC cases No. (%)   Chronic HBV carriers No. (%)   OR[^a^](#tfn_001){ref-type="table-fn"} (95% CI)   *P*-value[^a^](#tfn_001){ref-type="table-fn"}
  -------------- ----------- ------------------- ------------------------------ ------------------------------------------------- -----------------------------------------------
                             *n* = 1186          *n* = 508                                                                        
                 TT          987 (83.2)          449 (88.4)                     Reference                                         
  Shandong set   TG          192 (16.2)          58 (11.4)                      1.51 (1.10--2.07)                                 0.010
                 GG          7 (0.6)             1 (0.2)                        NC                                                
                 TG + GG     199 (16.8)          59 (11.6)                      1.53 (1.12--2.10)                                 0.007
                             *n* = 620           *n* = 1200                                                                       
                 TT          509 (82.1)          1062 (88.4)                    Reference                                         
  Jiangsu set    TG          105 (16.9)          136 (11.3)                     1.49 (1.11--1.99)                                 0.008
                 GG          6 (1.0)             2 (0.2)                        NC                                                
                 TG + GG     111 (17.9)          138 (11.5)                     1.57 (1.18--2.09)                                 0.002
                             *n* = 1806          *n* = 1708                                                                       
                 TT          1496 (82.8)         1511 (88.5)                    Reference                                         
  Pooled         TG          297 (16.5)          194 (11.4)                     1.56 (1.24--1.97)                                 1.76 × 10^−4^
                 GG          13 (0.7)            3 (0.2)                        NC                                                
                 TG + GG     310 (17.2)          197 (11.6)                     1.52 (1.19--1.94)                                 0.001

Note: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; NC, not calculated.

HCC case vs. chronic HBV carriers, data were calculated by logistic regression with adjustment for age, sex, smoking and drinking.

Unconditional logistic regression analysis was used to examine associations between the *GLB1* rs4678680 SNP and HBV-related HCC risk in Shandong and Jiangsu sets (Table [1](#T1){ref-type="table"}). The rs4678680 G allele was showed to be risk allele; individuals with the TG genotype had an OR of 1.51 (95% CI = 1.10--2.07, *P* = 0.010, Shandong set) or 1.49 (95% CI = 1.11--1.99, *P* = 0.008, Jiangsu set) for developing HBV-related HCC, respectively, compared with individuals with the TT genotype (Table [1](#T1){ref-type="table"}). It was also found that carriers of the rs4678680 TG or GG genotype showed significantly and consistently increased risk to develop HBV-related HCC compared with the TT carriers in both case-control sets (Shandong set: OR = 1.53, 95% CI = 1.12--2.10, *P* = 0.007; Jiangsu set: OR = 1.57, 95% CI = 1.18--2.09, *P* = 0.002). In the pooled analyses, we observed that the odds of having the rs4678680 TG genotype in cases was 1.56 (95% CI = 1.24--1.97, *P* = 1.76 × 10^−4^) compared with the TT genotype. Similarly, the rs4678680 TG or GG genotype carriers showed a 1.52-fold increased HCC risk compared with the TT genotype carriers (95% CI = 1.19--1.94, *P* = 0.001).

The risk of HBV-related HCC associated with the *GLB1* rs4678680 genotypes was further examined by stratifying for sex (Table [2](#T2){ref-type="table"}). A significantly increased risk of HCC associated with the rs4678680 TG or GG genotype compared with the TT genotype was observed in males (Shandong set: OR =1.60, 95% CI = 1.15--2.23; *P* = 0.006; Jiangsu set: OR = 1.59, 95% CI = 1.17--2.16; *P* = 0.003). However, this genetic polymorphism was not significantly associated with HCC risk in females (all *P* \> 0.05). In the stratification analyses with age, elevated risk of HCC associated with the *GLB1* rs4678680 TG or GG genotype was only observed among individuals aged older than 57 years (Shandong set: OR = 1.63, 95% CI = 1.01--2.62; *P* = 0.047), but not among individuals aged 57 years or younger (Shandong set: OR = 1.46, 95% CI = 0.96--2.21; *P* = 0.076) (Table [3](#T3){ref-type="table"}). Similar results were observed among individuals aged older than 57 years in Jiangsu set (rs4678680 TG or GG genotype: OR = 2.10, 95% CI = 1.37--3.21; *P* = 0.001). Interestingly, the rs4678680 TG or GG genotype was also significantly associated with increased HCC risk in drinkers compared to the TT genotype in both sets (Shandong: OR = 1.90, 95% CI = 1.26--2.86, *P* = 0.002; Jiangsu: OR = 1.76, 95% CI = 1.21--2.57, *P* = 0.003) (Table [4](#T4){ref-type="table"}). However, no such associations was observed among non-drinkers (all *P* \> 0.05).

###### Risk of HBV-related HCC associated with *GLB1* rs4678680 G \> T genotypes by sex

  Studies        Genotypes   Males                     Females                                                                           
  -------------- ----------- ------------ ------------ ----------------------- ----------- ------------ ------------ ------------------- -------
                             *n* = 1018   *n* = 425                                        *n* = 168    *n* = 83                         
                 TT          848 (83.3)   373 (87.8)   Reference                           139 (82.7)   76 (91.6)    Reference           
  Shandong set   TG          164 (16.1)   51 (12.0)    **1.58 (1.13--2.21)**   **0.008**   28 (16.7)    7 (8.4)      1.39 (0.54--3.60)   0.500
                 GG          6 (0.6)      1 (0.2)      NC                                  1 (0.6)      0 (0)        NC                  
                 TG + GG     170 (16.7)   52 (12.2)    **1.60 (1.15--2.23)**   0.006       29 (17.3)    7 (8.4)      1.47 (0.57--3.77)   0.428
                             *n* = 531    *n* = 998                                        *n* = 89     *n* = 202                        
                 TT          437 (82.3)   884 (88.6)   Reference                           72 (80.9)    178 (88.1)   Reference           
  Jiangsu set    TG          88 (16.6)    112 (11.2)   **1.50 (1.11--2.05)**   **0.011**   17 (19.1)    24 (11.9)    1.36 (0.38--4.83)   0.639
                 GG          6 (1.1)      2 (0.2)      NC                                  0 (0)        0 (0)        NC                  
                 TG + GG     94 (17.7)    114 (11.4)   **1.59 (1.17--2.16)**   **0.003**   17 (19.1)    24 (11.9)    1.36 (0.38--4.83)   0.639

Note: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; NC, not calculated.

HCC case vs. chronic HBV carriers, data were calculated by logistic regression with adjustment for age, smoking and drinking.

###### Risk of HBV-related HCC associated with *GLB1* rs4678680 G \>T genotypes by age

  Studies        Genotypes                Age          (≤ 57 years)                             Age          (\> 57 years)           
  -------------- ----------- ------------ ------------ ------------------- ------- ------------ ------------ ----------------------- -----------
                             *n* = 627    *n* = 262                                             *n* = 559    *n* = 246               
                 TT          516 (82.3)   228 (87.0)   Reference                   471 (84.3)   221 (89.8)   Reference               
  Shandong set   TG          108 (17.2)   33 (12.6)    1.46 (0.96--2.23)   0.077   84 (15.0)    25 (10.2)    1.56 (0.96--2.51)       0.072
                 GG          3 (0.5)      1 (0.4)      NC                          4 (0.7)      0 (0)        NC                      
                 TG + GG     111 (17.7)   34 (13.0)    1.46 (0.96--2.21)   0.076   88 (15.7)    25 (10.2)    **1.63 (1.01--2.62)**   **0.047**
                             *n* = 315    *n* = 633                                *n* = 305    *n* = 567                            
                 TT          265 (84.1)   552 (87.2)   Reference                   244 (80.0)   510 (89.9)   Reference               
  Jiangsu set    TG          44 (14.0)    79 (12.5)    1.06 (0.70--1.60)   0.791   61 (20.0)    57 (10.1)    **2.10 (1.37--3.21)**   **0.001**
                 GG          6 (1.9)      2 (0.3)      NC                          0 (0)        0 (0)        NC                      
                 TG + GG     50 (15.9)    81 (12.8)    1.19 (0.80--1.78)   0.388   61 (20.0)    57 (10.1)    **2.10 (1.37-3.21)**    **0.001**

Note: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; NC, not calculated.

HCC case vs. chronic HBV carriers, data were calculated by logistic regression with adjustment for sex, smoking and drinking.

###### Risk of HBV-related HCC associated with *GLB1* rs4678680 G \> T genotypes by alcohol drinking

  Studies        Genotypes   Nondrinkers                Drinkers                                                                      
  -------------- ----------- ------------- ------------ ------------------- ------- ------------ ------------ ----------------------- -----------
                             *n* = 410     *n* = 195                                *n* = 776    *n* = 313                            
                 TT          349 (85.1)    168 (86.2)   Reference                   638 (82.2)   281 (89.8)   Reference               
  Shandong set   TG          59 (14.4)     26 (13.3)    1.16 (0.70--1.92)   0.578   133 (17.2)   32 (10.2)    **1.82 (1.21--2.75)**   **0.004**
                 GG          2 (0.5)       1 (0.5)      NC                          5 (0.6)      0 (0)        NC                      
                 TG+GG       61 (14.9)     27 (13.8)    1.14 (0.69--1.87)   0.620   138 (17.8)   32 (10.2)    **1.90 (1.26--2.86)**   **0.002**
                             *n* = 156     *n* = 706                                *n* = 464    *n* = 494                            
                 TT          133 (85.3)    629 (89.1)   Reference                   376 (81.1)   433 (87.7)   Reference               
  Jiangsu set    TG          20 (12.8)     76 (10.8)    1.25 (0.68--2.29)   0.468   85 (18.3)    60 (12.1)    **1.72 (1.17--2.51)**   **0.006**
                 GG          3 (1.9)       1 (0.1)      NC                          3 (0.6)      1 (0.2)      NC                      
                 TG + GG     23 (14.7)     77 (10.9)    1.42 (0.79--2.53)   0.240   88 (18.9)    61 (12.3)    **1.76 (1.21--2.57)**   **0.003**

Note: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval; NC, not calculated.

HCC case vs. chronic HBV carriers, data were calculated by logistic regression with adjustment for age, sex and smoking.

We next examined whether the HCC susceptibility SNP rs4678680 has an allele-specific impact on *GLB1* expression using HCC tissues since it locates in a 18 kb upstream region of *GLB1*. As shown in Figure [1](#F1){ref-type="fig"}, we found that there were significantly higher *GLB1* mRNA levels (mean ± SD) in HCC tissues compared to normal tissues (313.3 ± 33.93 vs. 189.9 ± 21.1; *P* = 0.003). Subjects with the rs4678680 TG or GG genotype had significantly higher *GLB1* mRNA levels than those with the TT genotypes in normal tissues (TG or GG: 367.5 ± 40.2 \[*n* = 9\], TT: 155.9 ± 20.6 \[*n* = 47\]; *P* = 0.001). Similar results were observed when the *GLB1* mRNA levels were compared between rs4678680 TG or GG and TT genotypes in HCC tissues (TG or GG: 590.7 ± 32.2 \[*n* = 9\], TT: 260.1 ± 35.0 \[*n* = 47\]; *P* = 0.001) (Figure [1](#F1){ref-type="fig"}).

![*GLB1* mRNA expression in fifty-six pairs of HCC-normal liver tissues\
(**A**) There were higher *GLB1* mRNA expression in HCC tissues than those in normal liver tissues. (**B**) *GLB1* mRNA expression in normal liver tissues grouped by *GLB1* rs4678680 genotypes. (**C**) *GLB1* mRNA expression in HCC tissues grouped by *GLB1* rs4678680 genotypes.](oncotarget-07-56501-g001){#F1}

DISCUSSION {#s3}
==========

In the current study, we examined the association between the *GLB1* rs4678680 SNP and risk of developing HBV-related HCC in a case-control design. Although the genetic predisposition to HCC of the *GLB1* rs4678680 polymorphism was firstly identified in Korean populations via GWAS, this is still the first validation study with relative large sample size in different ethnic populations. We found significantly increased HCC risk among individuals with the *GLB1* rs4678680 TG or GG genotype compared with those with TT genotype in Chinese. In the genotype-phenotype correlation analyses of fifty-six human liver tissue samples, rs4678680 TG or GG was associated with a statistically significant increase of *GLB1* mRNA expression.

The *GLB1* gene provides instructions for producing an enzyme called β-galactosidase. This enzyme is located in lysosomes, which are compartments within cells that break down and recycle different types of molecules. Within lysosomes, GLB1 helps break down certain molecules, including substances called GM1 ganglioside and keratan sulfate. Caldwell et al. found that GLB1 activity is the only biomarker that accurately identifies a small and heterogeneous population of non-proliferating premalignant cells in the pancreas, indicating the utility of GLB1 to predict the senescent state in pancreatic preneoplasia \[[@R13]\]. Additionally, increased GLB1 is a valuable marker in formalin-fixed paraffin-embedded tissues for the senescence-like phenotype and associates with improved prostate cancer outcomes \[[@R16]\]. All these evidences support the involvement of GLB1 in carcinogenesis, possibly through regulating cell senescence.

Several limitations may exist in this case-control study. First, because it was a hospital-based study and the cases were from hospitals, there might be inherent selection bias. As a result, it is crucial to confirm these observations in a population-based prospective study. Second, the statistical power for gene-covariate interaction analyses may be limited. Third, since the *P value* for association between the *GLB1* rs4678680 SNP and HCC risk in the current study are not less that 10^−7^, it is possible that these polymorphisms may not be identified by the aforementioned four large scale HCC GWAS in Chinese \[[@R7]--[@R10]\].

In summary, our study elucidated that the *GLB1* rs4678680 polymorphism was associated with risk of HBV-related HCC in Chinese populations, highlighting the involvement of *GLB1* and cell senescence in etiology of HCC.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

This study consisted of two case-control sets ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}): (a) Shandong set: 1186 individuals with HBV-related HCC, sex- and age-matched (± 5 years) 508 chronic HBV carriers were recruited at Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences (Jinan, Shandong Province, China). (b) Jiangsu set: 620 HBV-related HCC individuals from Huaian No. 2 Hospital (Huaian, Jiangsu Province, China) and sex- and age-matched 1200 chronic HBV carriers as controls. Cases and controls were recruited at Huaian No. 2 Hospital. The case-control sets has been reported previously \[[@R17]\]. A total of 56 pairs of HCC tissue specimens from 56 HCC individuals recruited in this study. All HCC individuals received curative resection in Huaian No. 2 Hospital or Qianfoshan Hospital, Shandong University. Prior to the surgery, no HCC individuals received any local or systemic anticancer treatments. All subjects were ethnic Han Chinese. At recruitment, the written informed consent was obtained from each subject. This study was approved by the institutional Review Boards of Shandong Cancer Hospital, Qianfoshan Hospital and Huaian No. 2 Hospital.

SNP genotyping {#s4_2}
--------------

The *GLB1* rs4678680 polymorphism was analyzed by the MassArray system (Sequenom Inc., San Diego, California, USA). *GLB1* rs4678680 PCR primers are 5′-ACGTTGGATGAGTCCAAGCCTGCTTTCTTC-3′ (Forward) and 5′-ACGTTGGATGTCTGCCGAGTTGT TGCAAAG-3′ (Reverse). *GLB1* rs4678680 UEP_SEQ primer is 5′-cctcaTGCTTTCTTCCCTTTTCT-3′. *GLB1* rs4678680 EXT1_SEQ primer is 5′-cctcaTGCTTTCT TCCCTTTTCTG-3′. *GLB1* rs4678680 EXT2_SEQ primer is 5′-cctcaTGCTTTCTTCCCTTTTCTT-3′. A 15% blind, random sample of study subjects was genotyped in duplicates and the reproducibility was 100%.

Real-time analyses of GLB1 mRNA {#s4_3}
-------------------------------

SYBR-Green real-time quantity PCR method was used to examine *GLB1* mRNA levels in normal liver tissues as described previously \[[@R18]--[@R20]\]. Total cellular RNA was isolated and converted to cDNA using the ReverTra Ace qPCR RT Kit (TOYOBO). Relative gene expression quantitation for *GLB1* and *β-actin* as an internal reference gene was carried out using the ABI 7500 real-time PCR system in triplicates. The primers used for *GLB1* were 5′- GTCTATTCTTCTCCGCTCCT −3′ and 5′- TGTGCTCCATCAGTGGTAA −3′; and for *β-actin* were 5′-GGCGGCACCACCATGTACCCT-3′ and 5′-AGGGGCCGGACTCGTCATACT-3′. The expression of individual *GLB1* mRNA measurements was measured relative to expression of *β-actin* mRNA using the method as described previously \[[@R21]\].

Statistic analyses {#s4_4}
------------------

The differences in demographic variables and genotype distributions of the *GLB1* rs4678680 SNP between cases and controls were examined via Pearson\'s χ^2^ test. The associations between genotypes of *GLB1* rs4678680 and HBV-related HCC risk were estimated by ORs and their 95% CIs computed by logistic regression models. All ORs were adjusted for age, sex, smoking or drinking status, where it was appropriate. Kruskal-Wallis one-way analysis of variance tests were performed to calculate *GLB1* mRNA expression differences between different rs4678680 genotype carriers. A *P* value of less than 0.05 was used as the criterion of statistical significance, and all statistical tests were two-sided. All analyses were performed using SPSS 16.0 (SPSS Inc.).

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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